-16%

est. 2Y upside i

HealthcareSeries D+

Rank

#3258

Sector

Biotechnology

Est. Liquidity

~4Y

Data Quality

Data: Low

Given the severe preference overhang ($1.13B vs $2.2B entry), high incumbent threat, and lack of revenue, expected equity upside is -16% over 2-4 years.

Last updated: July 3, 2026

Bull (10%)+140%

Successful clinical data for shingles vaccine (Phase III) and bispecific (Phase I) drives partnership or IPO at 3x entry ($6.6B). Net of 20% dilution, return 140%.

Base (50%)+20%

Pipeline progresses with moderate partnership income; exit at $3.3B (1.5x entry). After 20% dilution, return 20%.

Bear (40%)-100%

Clinical failure or prolonged development leads to exit below $1.13B (total funding). Preference stack wipes out common equity: -100%.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Funding Intensity

5136%

Total funding of $1.13B represents 51% of the $2.2B entry valuation, meaning common stock is deeply subordinated.

Dilution Risk

high

With no revenue and high burn, a down round or large raise is likely within 2 years, diluting existing holders by ~20%.

Secondary Liquidity

limited

Secondary market exists but at a 40% discount to analyst valuation, suggesting limited liquidity for common shares.

Questions to Ask at the Interview

Strategic questions based on AbogenBio's data — designed to show you've done your homework.

  • 1

    “How does Abogen's mRNA-LNP platform differentiate from Moderna and BioNTech for non-COVID applications?”

  • 2

    “What is the expected timeline to first product revenue, and what are the key partnership milestones?”

  • 3

    “Given the $1.13B in total funding and no revenue, how much dilution should employees expect in the next raise?”

Community

Valuation Sentiment

Our model estimates -16% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.